Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

Malignant Pleural Mesotheliomas Clinical Trial

— VITMPM  

Official title:

To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02603315
• Other study ID #: DR-81
• Status: Completed
• Phase: N/A
• First received: October 28, 2015
• Last updated: May 29, 2016
• Start date: October 2015
• Est. completion date: May 2016

Study information

• Verified date: October 2015
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Egypt: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Description:

This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 39 Years to 84 Years

Eligibility

Inclusion Criteria:

• Histopathological confirmation of malignant pleural mesothelioma .

• Full clinical data.

• Availability for follow up: Personal communication will be attempted in order to collect missing information.

3-The files of all patients will be reviewed to analyze the following :

• Operative data if done .

• Pathological review and immunohistochemistry.

• Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test)

• Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\S and MRI ).

• Treatment protocols applied: Radiotherapy and Chemotherapy.

• Response and survival after treatment .

Exclusion Criteria:

• cases not receive chemotherapy ,on available of evaluation after treatment

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Malignant Pleural Mesotheliomas
• Mesothelioma

Intervention

Other:
• marker CD74 and vascular endothelial growth factor VEGF
correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment

Locations

Country	Name	City	State
Egypt	Ain Shams University Hospital	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival	The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment	3-4 months	No
Secondary	assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74	The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment	3-4 months	No